CA2161011A1 — Xanthine derivatives
Assigned to KH Neochem Co Ltd · Expires 1995-08-31 · 31y expired
What this patent protects
A xanthine derivative represented by general formula (I) or a pharmacologically acceptable salt thereof, wherein R1, R2 and R3 are the same or different from one another and each represents hydrogen, lower alkyl, lower alkenyl or lower alkynyl; R4 represents lower alkyl or (un)su…
USPTO Abstract
A xanthine derivative represented by general formula (I) or a pharmacologically acceptable salt thereof, wherein R1, R2 and R3 are the same or different from one another and each represents hydrogen, lower alkyl, lower alkenyl or lower alkynyl; R4 represents lower alkyl or (un)substituted aryl; R5 and R6 are the same or different from each other and each represents hydrogen, lower alkyl or lower alkoxy, or R5 and R6 are combined together to represent -O-(CH2)p-O- (wherein p represents an integer of 1 to 3); n represents 0, 1 or 2; and m represents 1 or 2. The compound has an adenosine A2 receptor antagonism and is useful for treating or preventing various diseases caused by the hyperfunctioning of adenosine A2 receptors, such as Parkinson's disease, senile dementia, depression, asthma or osteoporosis.
Drugs covered by this patent
- Nourianz (ISTRADEFYLLINE) · Kyowa Kirin
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.